伦瓦提尼布治疗不可切割的形甲状腺癌:多机构研究中的现实世界经验
Takuya Mikoshiba1, Mariko Sekimizu2, Takeyuki Kono2
1Department of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan. t-mikoshiba@keio.jp.
Endocrine
|June 28, 2025
概括
伦瓦提尼布在治疗无塑性甲状腺癌 (ATC) 方面表现出适度的疗效. 用降低剂量开始治疗可能会改善治疗效益和生存结果,对于无法耐受标准24毫克每日剂量的患者.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 无塑性甲状腺癌 (ATC) 是一种罕见的,具有不良预后的侵袭性甲状腺癌.
- 伦瓦提尼布在日本已被批准用于不可切割的ATC,但由于副作用,通常需要降低剂量.
研究的目的:
- 评估伦瓦提尼布在ATC患者的治疗效果.
- 评估与 ATC 患者减少 lenvatinib 剂量相关的结果.
主要方法:
- 对16名ATC患者进行了回顾性评估,这些患者接受了lenvatinib治疗.
- 在接受标准24毫克每日剂量的患者与降低初始剂量的患者之间,总生存 (OS) 和无进展生存 (PFS) 的比较.
主要成果:
- 伦瓦提尼布的客观响应率为31%,平均存活时间为2.2个月,PFS为1.7个月.
- 接受降低初始剂量的患者与接受标准24mg剂量的患者相比,表现得更好 (中位数OS 6.2个月,PFS 2.4个月) (中位数OS 2.0个月,PFS 1.4个月).
结论:
- 伦瓦提尼布在不可切割的ATC中提供中等效果.
- 降低伦瓦替尼的初始剂量可能会提高ATC患者的治疗效益和耐受性.
- 当其他向疗法无法使用时,伦瓦提尼布是ATC的潜在治疗选择.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227


